Flavio Rocha, MD
Surgical Oncology · Seattle, WANPI 1609938778
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Medtronic at 55.7% of the total. Reporting peaked in 2021 at $14,653 and has fallen 91.8% since, to $1,201 in 2025. Among surgical oncology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 38 payments — averaging $702.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$15K
- AstraZeneca$11K
- Intera Oncology, Inc$176
- Integra Lifesciences Corporation$170
- Astrazeneca UK Limited$135
- Genentech USA, Inc.$125
- plus $299 from 5 others
Across 2 payments — averaging $22,980 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$37K
- Gunze Limited$9K
What the payments were for
- Consulting fees$10,47239%
- Speaking & faculty fees$13,50051%
- Travel & lodging$6512%
- Food & beverage$2,0558%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 16 | $14,848 |
| AstraZeneca | 13 | $10,923 |
| Intera Oncology, Inc | 1 | $176 |
| Integra Lifesciences Corporation | 1 | $170 |
| Astrazeneca UK Limited | 1 | $135 |
| Genentech USA, Inc. | 1 | $125 |
| Angiodynamics, Inc. | 1 | $91 |
| Medical Device Business Services, Inc. | 1 | $85 |
| Sirtex Medical Inc | 1 | $77 |
| Boehringer Ingelheim | 1 | $23 |
| Johnson & Johnson | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$8,445
- Signia$982
- INTERA$176
- CODMAN CERTAS$170
- CUSA CLARITY$170
- Avastin$125
How this compares
$26,678 in reported general payments places this provider in the 95th percentile of 31 surgical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other surgical oncology in Seattle
- Evan OngSeattle$18K
- Benjamin AndersonSeattle$15K
- Kevin LabadieSeattle$11K
- Jeremy SharibSeattle$9K
- Harveshp MogalSeattle$8K
- Meghan FlanaganSeattle$7K
- Sara JavidSeattle$6K
- Venu PillarisettySeattle$6K
- Christopher ChildersSeattle$4K
- Laura LazarusSeattle$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.